BR9708037A - Method for the treatment of substance abuse - Google Patents

Method for the treatment of substance abuse

Info

Publication number
BR9708037A
BR9708037A BR9708037A BR9708037A BR9708037A BR 9708037 A BR9708037 A BR 9708037A BR 9708037 A BR9708037 A BR 9708037A BR 9708037 A BR9708037 A BR 9708037A BR 9708037 A BR9708037 A BR 9708037A
Authority
BR
Brazil
Prior art keywords
substance abuse
treatment
olanzapine
administering
patient
Prior art date
Application number
BR9708037A
Other languages
Portuguese (pt)
Inventor
Charles Merritt Beasley Jr
Kurt Rasmussen
Gary Dennis Tollefsen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606615.4A external-priority patent/GB9606615D0/en
Priority claimed from GBGB9606617.0A external-priority patent/GB9606617D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9708037A publication Critical patent/BR9708037A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Disintegrating Or Milling (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

The invention provides a method for treating substance abuse comprising administering an effective amount of olanzapine or pharmaceutically acceptable salt thereof to a patient in need thereof.
BR9708037A 1996-03-11 1997-03-10 Method for the treatment of substance abuse BR9708037A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1316096P 1996-03-11 1996-03-11
US1316196P 1996-03-11 1996-03-11
GBGB9606615.4A GB9606615D0 (en) 1996-03-29 1996-03-29 Method for treating alcohol addiction
GBGB9606617.0A GB9606617D0 (en) 1996-03-29 1996-03-29 Method for treating substance abuse
PCT/US1997/003404 WO1997033586A1 (en) 1996-03-11 1997-03-10 Method for treating substance abuse

Publications (1)

Publication Number Publication Date
BR9708037A true BR9708037A (en) 1999-07-27

Family

ID=27451428

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708037A BR9708037A (en) 1996-03-11 1997-03-10 Method for the treatment of substance abuse

Country Status (15)

Country Link
EP (1) EP1007050B1 (en)
JP (1) JP2000517287A (en)
KR (1) KR19990087714A (en)
CN (1) CN1213308A (en)
AT (1) ATE295731T1 (en)
BR (1) BR9708037A (en)
CA (1) CA2248738A1 (en)
CZ (1) CZ290398A3 (en)
DE (1) DE69733321D1 (en)
IL (1) IL126158A0 (en)
NO (1) NO984196L (en)
NZ (1) NZ331845A (en)
PL (1) PL328924A1 (en)
TR (1) TR199801801T2 (en)
WO (1) WO1997033586A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
WO2000030649A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
MXPA03006251A (en) * 2001-01-12 2004-10-15 Innovation Ventures Llc Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
AU2067297A (en) 1997-10-01
AU725940B2 (en) 2000-10-26
EP1007050A4 (en) 2000-06-14
JP2000517287A (en) 2000-12-26
ATE295731T1 (en) 2005-06-15
KR19990087714A (en) 1999-12-27
CN1213308A (en) 1999-04-07
EP1007050B1 (en) 2005-05-18
DE69733321D1 (en) 2005-06-23
IL126158A0 (en) 1999-05-09
NZ331845A (en) 2000-09-29
PL328924A1 (en) 1999-03-01
TR199801801T2 (en) 1998-12-21
NO984196D0 (en) 1998-09-11
CA2248738A1 (en) 1997-09-18
CZ290398A3 (en) 1999-10-13
WO1997033586A1 (en) 1997-09-18
EP1007050A1 (en) 2000-06-14
NO984196L (en) 1998-11-03

Similar Documents

Publication Publication Date Title
ES2178157T3 (en) TREATMENT OF ARRITMIAS THROUGH THE INHIBITION OF A MULTIFUNCTIONAL KINASE PROTEIN DEPENDENT ON CALCIUM / CALMODULIN.
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
DE69620691D1 (en) Therapeutic agent for the treatment of hypercholesterolemia
YU42298A (en) The use of olanzapine in praparation of medicine useful for treating acute pain
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
IL120303A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
EA199800864A1 (en) METHOD OF TREATMENT FOR PATIENTS CAUSED BY MIGRAINE
BR9708037A (en) Method for the treatment of substance abuse
BR9908190A (en) Processes for treating female-specific pain in a female patient, and for treating chronic pain in a female patient
HUP9903679A2 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
NO984198L (en) Procedure for the treatment of aggression
EA199800820A1 (en) METHOD OF TREATING ABUSE OF MEDICINES
DE69800906D1 (en) Use of olanzapine in the manufacture of a medicament for the treatment of cerebral focal ischemia
EA199800818A1 (en) Method of treating insomnia
YU40198A (en) Method for treating substance abuse
EE04951B1 (en) Use of R - (+) - alpha- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol for the treatment of sleep disorders
ID28817A (en) USE OF TETRAHIDROPIRIDIN (OR 4-HIDROPIPERIDIN) -BUTILAZOL DRUGS IN THE MAKING OF DRUGS FOR PAIN TREATMENT
DK0872238T3 (en) Use of olanzapine in the manufacture of a drug for neuroprotectin
BR7500523U (en) Disposable socks for medical treatment
DK8893D0 (en) MEDICAMENT FOR TREATMENT OR PREVENTION OF DISEASE

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]